PRCXI has completed a nearly 100 million RMB Series A financing round. This round was led by CITIC Capital, with continued investment from Qiming Venture Partners.
Previously, the company had secured multiple rounds of funding with participation from renowned institutions including Wuzhong Financial Holding Group, Wuzhong Rongyue Investment, Qiming Venture Partners, and SAIF Partners. The new capital infusion will vigorously accelerate PRCXI's R&D, global expansion, and popularization of its "Life Science Full-Process Automation Intelligent Ecosystem," empowering broader scientific research and industrial applications.
Ten years of deep cultivation, to create automation popularization hard core strength
Since its establishment in 2014, PRCXI has always been plowing into the field of life science laboratory automation, focusing on the research, development and production of laboratory automation systems and consumables, taking the independent innovation of the underlying core technology as the foundation, supported by the intelligent manufacturing synergy of the whole industrial chain, and unswervingly carrying out the mission of "the popularizer of life science automation". The company has successfully realized the breakthrough from key technology. The company has successfully realized the leapfrog development from key technology breakthroughs to the construction of a complete ecosystem, and has set up R&D and production bases in Suzhou, Nanjing, Xiangyang and Guangzhou.
Wide coverage of products and ecology: PRCXI has built a system of automation solutions covering dozens of cutting-edge fields such as genomics, cell biology, drug discovery, protein science, analytical chemistry, synthetic biology, etc., and has landed more than a hundred laboratory scenarios and application solutions.
Recognized and trusted by customers and the market: PRCXI's services cover more than 10 countries and regions around the world, such as the United States, Japan, Germany, South Korea, etc., with a total of more than 6,000 installations and more than 3,000 users, covering medical institutions, scientific research institutes, pharmaceutical and biotechnology enterprises, industrial and governmental organizations, and so on.
Tackling Research Pain Points: Introducing the PRCXI Smart Lab Hub
Confronting the immense challenges posed to traditional laboratory models by exponential growth in experimental data, increasingly complex workflows, and rising quality demands in life science research, PRCXI has innovatively launched an intelligent laboratory management system centered on "Omniscenario, Full-Chain, Pan-Ecosystem" capabilities. Supported by the company's self-developed intelligent hardware array, this system establishes an end-to-end digital closed loop from sample processing to data analysis, delivering a one-stop digital solution. It significantly enhances lab management efficiency, experimental traceability, and overall scientific capabilities – ultimately empowering more laboratories to achieve digital transformation and elevating industry-wide management standards.
Globalization, building an efficient and agile supply chain
In order to support the globalization strategy and market expansion, PRCXI has built a global supply chain network covering the whole chain of "R&D, production and service". Through the deployment of advanced digital supply chain management system, the company realizes efficient collaboration and optimal allocation of cross-border resources.
Meanwhile, PRCXI is accelerating the penetration of its laboratory intelligent solutions in the global market by combining the localized technology adaptation capability and rapid response service mechanism, and continuously improving its international market share and brand influence.
Zhu Bin, founder of PRCXI, said, "Life science laboratory automation is the core facility for efficiency improvement and intelligent transformation. This round of financing will promote the company's strategic upgrade from a supplier of equipment and consumables to a full-process eco-service provider, relying on the underlying technology R&D and manufacturing advantages, and continue to output cost-effective intelligent solutions to help global scientific research and industrial customers in their intelligent transformation."
CITIC Capital invested in the project manager of Zhongdanwei, said, "With the development of AI and life science technology, experimental throughput, data quality and data traceability are becoming more and more important, and laboratory automation is expected to solve the problems of traditional manual operation. PRCXI is expected to accelerate the popularization of laboratory automation through ecological product system by virtue of its multi-technology cross R&D capability and scale manufacturing advantage."
Dr. Kan Chen, Partner and Co-Head of Healthcare Industry at Qiming Ventures, said, "PRCXI, relying on the strengths of its team with both R&D and commercialization capabilities, will continue to promote the intelligent development of life sciences through its open ecosystem strategy, with laboratory automation as the core focus. We expect PRCXI to lead the efficiency innovation and industrial upgrading in the life science field through standardized solutions."
About CITIC Capital
CITIC Capital was incorporated in Beijing on July 31, 2009 and is wholly owned by CITIC Capital Securities Company Limited with a registered capital of RMB 3.5 billion, specializing in private equity fund management. The funds managed by CITIC Capital include equity direct investment funds, market-oriented mother funds and infrastructure investment funds, etc. The investment targets are mainly enterprises with high growth and those with merger and acquisition value in industrial integration, and the industry sectors cover science and technology communication, medical and pharmaceutical, clean energy, new materials, advanced manufacturing, military industry, energy conservation and environmental protection, culture, tourism and consumption, and infrastructure. CITIC Capital has more than 80 funds under management, with a cumulative management scale of over 100 billion RMB.
About Qiming Venture Capital
Qiming Venture Capital was founded in 2006. Currently, Qiming Ventures manages 11 USD funds and 7 RMB funds, with total assets under management amounting to USD 9.5 billion. Since its inception, Qiming Ventures has focused on investing in early-stage and growth-stage companies in the Technology and Consumer (T&C) and Healthcare industries.
To date, Qiming Ventures has invested in more than 580 fast-growing innovative companies, of which more than 210 are listed on the New York Stock Exchange (NYSE), NASDAQ, Hong Kong Stock Exchange (HKSE), Shanghai Stock Exchange (SSE) and Shenzhen Stock Exchange (SZSE), or exited through mergers and acquisitions, and more than 80 have become industry-recognized unicorns or super unicorns.